The Pennsylvania State University, Department of Veterinary & Biomedical Sciences, University Park, PA 16802, USA.
Vaccine. 2011 Jul 26;29(33):5347-54. doi: 10.1016/j.vaccine.2011.05.092. Epub 2011 Jun 12.
Mycoplasma bovis is an etiologic agent of pneumonia, arthritis, and otitis in young calves, such as those found in the special-fed veal industry. We conducted a blinded, controlled trial of two commercially available M. bovis bacterin vaccines for the prevention of respiratory disease in calves associated with M. bovis infection. Calves were randomly assigned to a subcutaneous treatment of vaccine A (n=50), adjuvant A (n=50), vaccine B (n=50), or 0.9% sterile saline solution (n=50) beginning at 27 days of age. Upper-respiratory tract colonization was not impacted by vaccination status. Vaccine A significantly reduced the presence of lung lesions (p=0.0325), however there was no significant reduction of M. bovis in lung lesions. Vaccine B did not significantly reduce total lung lesions or M. bovis-specific lung lesions. The relative risk was determined to be 0.56, 1.0, and 1.36 for vaccine A, adjuvant A, and vaccine B, respectively. There was no association between the total specific antibody isotype (IgM, IgG1, IgG2, IgA) concentrations or M. bovis antibodies and the M. bovis-associated morbidity in the veal calves. Under the field conditions of this study, observed vaccine efficacy for vaccine A and vaccine B was 44% and less than 1%, respectively.
牛支原体是一种引起幼牛肺炎、关节炎和中耳炎的病原体，如在特殊饲养的小牛肉产业中发现的病原体。我们进行了一项盲法、对照试验，评估了两种市售的牛支原体巴氏杆菌疫苗预防与牛支原体感染相关的犊牛呼吸道疾病的效果。将犊牛随机分配至 27 日龄时接受疫苗 A（n=50）、佐剂 A（n=50）、疫苗 B（n=50）或 0.9%无菌生理盐水（n=50）的皮下治疗。接种状态并不影响上呼吸道定植。疫苗 A 显著降低了肺部病变的存在（p=0.0325），但肺病变中的牛支原体数量没有显著减少。疫苗 B 并未显著降低总肺病变或牛支原体特异性肺病变。疫苗 A、佐剂 A 和疫苗 B 的相对风险分别为 0.56、1.0 和 1.36。牛支原体相关发病率与总特异性抗体同种型（IgM、IgG1、IgG2、IgA）浓度或牛支原体抗体之间没有关联。在本研究的现场条件下，观察到疫苗 A 和疫苗 B 的疫苗效力分别为 44%和小于 1%。
